about
P509
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR AgonistsA Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic MelanomaA Phase I Study of TPI 287 - Temozolomide Combination in MelanomaA Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersModified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic CancerAdoptive Transfer of MART1/Melan-A CTL for Malignant MelanomaTIL and Anti-PD1 in Metastatic MelanomaCP-675,206 In Patients With Advanced MelanomaStudy of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaAnalysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)Efficacy Study of TLN-232 in Patients With Recurring Metastatic MelanomaA Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant MelanomaTrial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant MelanomaStudy of Immune Responses in Patients With Metastatic MelanomaComparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma PatientsStudy of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating LymphocytesPost-ATU Study of NivolumabProspective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic MelanomaMechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney CancerTargeted Radionuclide Therapy for Metastatic Melanoma [131I] ICF 01012Dabrafenib and/or Trametinib Rollover Study
P921
Q61894700-2EA5B1C1-12C5-4076-927F-36932FD2BA80Q61909853-C44D725E-6683-419F-B3B7-3004264F8002Q61939180-C49C391F-2FC0-44F8-9E24-3A2E9FFA180BQ61965728-4D00ECF8-10B2-4EC3-BBC2-63E1D46B0FA0Q61965995-4F469B6B-28BC-4777-9743-92E5BBFDC542Q61978999-C338B7D0-D8D7-4F3A-A617-54290EBE6A7CQ62063124-B38CB97F-1E92-4920-84E3-02950A835B6CQ62110512-31EAC0F3-02BD-4A9D-B105-23316E665CA1Q62809792-72F5226F-46BF-44B1-9C0C-CE1A44C1AC1AQ62814848-D8590218-9448-463B-B013-974D9411CF87Q63063465-297CFE52-75E8-4F5E-B239-DD03801F05E3Q63063653-101875EE-D6AA-45CA-AAB2-C975CEA56FD2Q63319254-54BC6725-85B5-430D-9144-2971901F16EBQ63322830-8185D2DC-BDB7-4F5A-A749-9B92997D97EEQ63322831-EC9AEBFD-46FB-41A2-9B56-926FD1E520F3Q63337435-3EB833C4-F914-4F99-AC92-969AE354502CQ63339171-5191DB75-41E2-4788-BDC0-45B7509839CFQ63340650-5E3A4E2A-2D1C-491F-8442-042C0C0DA97AQ63534408-C3F253DB-21A3-4708-905F-86D5FE9D3959Q63571697-E97CE963-C687-4F74-98FE-88B4DF17CE39Q63577372-32CF6880-A31A-4C64-ACFB-AD81647F3EDDQ63577445-616275E8-4444-490D-830D-98B19C9A0DDBQ63592357-968FDA9F-33F5-423B-A4D2-47ED6C630765Q63811871-A41B96A0-F7B2-4960-85DA-0042BF5C9478
P921
description
Human disease
@en
مرض يصيب الإنسان
@ar
name
metastatic melanoma
@en
type
label
metastatic melanoma
@en
prefLabel
metastatic melanoma
@en